Nike Appoints Pfizer CFO Denton; Tariff Benefit Boosts Q4

(NKE) appointed David Denton, formerly Pfizer, Inc.'s (PFE) Executive Vice President and Chief Financial Officer, as its new Executive Vice President and CFO, effective August 17. Denton succeeds Matthew Friend, who will depart on September 4.

This leadership change coincides with Nike's announcement that its fourth-quarter results will include an unexpected benefit from tariff refunds, which was not factored into its prior guidance. Excluding this one-time benefit, the company anticipates its Q4 results will align with previous expectations, which projected a revenue decline of 2 percent to 4 percent, with China sales down approximately 20 percent.

Denton brings over 30 years of finance and operating leadership experience, including prior CFO roles at Lowe's Companies, Inc. from 2018 to 2022 and two decades at CVS Health Corp., and board service for Haleon and Tapestry.

President and CEO Elliott Hill stated Denton's experience will aid disciplined execution and long-term value creation as Nike transitions to a "Sport Offense operating model" for sustained growth.